New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 22, 2014
10:48 EDTATHN, SNDK, SWKS, YHOO, SHPG, CMG, IGT, MTG, NFLXOptions with decreasing implied volatility
Options with decreasing implied volatility: IGT YHOO LYK ATHN CMG SWKS NFLX SHPG SNDK MTG
News For IGT;YHOO;ATHN;CMG;SWKS;NFLX;SHPG;SNDK;MTG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
March 23, 2015
07:36 EDTSHPGPfizer should rise 'significantly' over next two years, says Jefferies
Jefferies analyst Jeffrey Holford told investors this morning that he expects shares of Pfizer (PFE) to appreciate "significantly" over the next two years. A survey of U.S. oncologists indicated the company's Ibrance drug will be used in 50% of first line hormonal therapy within one year, with off-label use in all lines of therapy including adjuvant, Holford noted. He thinks peak sales of the drug could top $13B, which is well above consensus. In addition, the analyst views Pfizer's Global Established Pharmaceutical business as being underappreciated by the market. Potential value creating options for the pharmaceutical giant include spinning off its GEP unit by 2017 and accretive acquisitions, with possible takeover targets being Shire (SHPG), Actavis (ACT), AstraZeneca (AZN) and GlaxoSmithKline (GSK), in the eyes of Holford. He added the stock to the firm's Franchise Picks list, which encompasses its best ideas. He also raised his price target for Pfizer to $45 from $42. The stock closed Friday up 10c to $34.25.
March 20, 2015
16:00 EDTNFLXOptions Update; March 20, 2015
Subscribe for More Information
10:00 EDTSHPGOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:45 EDTNFLXActive equity options trading on open
Subscribe for More Information
09:41 EDTSHPGBernstein global specialty pharma analyst holds analyst/industry conference call
Subscribe for More Information
08:12 EDTSHPGShire upgraded to Outperform from Market Perform at Bernstein
Bernstein upgraded Shire as the firm thinks that the stock's risk/reward ratio is positive following several new developments. Among these developments are the firm's belief that the company's orphan drug strategy looks increasingly strong, while the risks to the company's Vyvanse and mesalamines drugs look to have moderated and the company has several near-term, 2015 catalysts. Target $295.
March 19, 2015
16:01 EDTNFLXOptions Update; March 19, 2015
Subscribe for More Information
11:02 EDTNFLXOptions with increasing implied volatility
Options with increasing implied volatility: HLF RAD NFLX HLSS NOW
09:37 EDTNFLXActive equity options trading on open
Subscribe for More Information
08:18 EDTSNDKSanDisk to benefit from 3D NAND, says Morgan Stanley
Subscribe for More Information
06:15 EDTATHNathenahealth coverage transferred with an Outperform at RW Baird
Subscribe for More Information
05:57 EDTNFLXStocks with implied volatility above IV index mean; BBRY NFLX
Subscribe for More Information
March 18, 2015
17:50 EDTYHOOYahoo exits China operations, WSJ says
Subscribe for More Information
13:23 EDTNFLXBattleground: Oppenheimer weighs in on Netflix with positive note
The recent weakness in Netflix's (NFLX) stock has created a buying opportunity, Oppenheimer wrote in a note to investors today. Oppenheimer's upbeat note comes after research firm Stifel issued a positive note on the stock yesterday and a third firm, Evercore ISI, downgraded the shares to sell on Monday. BULLISH TAKE: Noting that Netflix's stock has dropped 15% from its 52-week high, Oppenheimer analyst Jason Helfstein said that the decline creates a good buying opportunity ahead a number of "tier 1" original show launches by the company. History indicates that tier 1 original shows have the most impact on the company's net subscriber additions, the analyst stated. Worries about competition have weighed on the shares, but Netflix can beat the competition by using its data to provide superior programming, according to the analyst. He kept a $483 price target and Outperform rating on the shares. Stifel analyst Scott Devitt yesterday stated that concerns about the company's competition are overdone, as Netflix's positioning in the U.S. is as strong as ever and continues to improve as it adds more content. Time Warner's (TWX) upcoming launch of a video on demand service called HBO Now is the primary cause of the decline in Netflix's stock, Devitt contended, noting he views the HBO Now launch as "a non-event" for Netflix. Most Netflix subscribers who obtain HBO Now will probably keep both services, Devitt believes. BEARISH TAKE: Evercore ISI analyst Ken Sena on Monday downgraded Netflix shares to Sell from Hold. Increased competition will force the company to raise its investments, and the return from those investments is uncertain, the analyst contended. In the U.S., technological advancements are enabling content providers to sell their programming to a wider range of Internet video distributors. Moreover, content providers themselves are now able to stream more of their programming online and obtain higher profits from doing so, Sena reported. Netflix's international expansion will not be sufficient to offset the increased competition, especially because foreign viewers are likely to watch less TV and be less interested in paying for TV content, the analyst believes, adding that Netflix will face even more competition overseas than in the U.S. Sela reduced his price target on the shares to $380 from $450. PRICE ACTION: In mid-afternoon trading, Netflix was little changed near $418 per share.
11:25 EDTSWKSStocks with call strike movement; SWKS MU
Subscribe for More Information
10:06 EDTYHOOYahoo to close Beijing R&D office, SCMP says
Subscribe for More Information
08:05 EDTNFLXNetflix weakness creates buying opportunity, says Oppenheimer
Subscribe for More Information
08:03 EDTSHPGTherapeuticsMD names Angus Russell, J. Martin Carroll as directors
TherapeuticsMD (TXMD) announced the appointment of two biopharmaceutical senior executives, Angus C. Russell and J. Martin Carroll, as independent members of its board of directors, and that Randall S. Stanicky has stepped down from the board of directors. Angus C. Russell served as CEO of Shire PLC (SHPG) from June 2008 until April 2013. J. Martin Carroll served as president and CEO of Boehringer Ingelheim Corp. U.S. from 2003 until 2011.
07:22 EDTSHPGShire looking for 'transformational' deal, Betaville blog says
Subscribe for More Information
06:01 EDTNFLXStocks with implied volatility above IV index mean; BBRY NFLX
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use